

Dear Pharmaceutical Manufacturer:

On November 19, 2010, the Texas Medicaid P&T Committee will review the products on the attached document: <TXM\_Classes\_For\_Review\_November\_2010.pdf>.

This file is also posted on our web site at:

[http://www.providersynergies.com/services/documents/TXM\\_Classes\\_For\\_Review\\_November\\_2010.pdf](http://www.providersynergies.com/services/documents/TXM_Classes_For_Review_November_2010.pdf)

On behalf of Texas HHSC and in preparation for this review, Provider Synergies invites you to submit supplemental rebate offers for these drug products.

Please submit offers via the Provider Synergies Secure FTP site (<https://www.secureftp.providersynergies.com/pssecure.html>.) using the attached Offer Form, which is also available at:

[http://www.providersynergies.com/services/documents/TXM\\_Offer\\_Form\\_2010\\_v4.xls](http://www.providersynergies.com/services/documents/TXM_Offer_Form_2010_v4.xls)

To complete the Offer Form, you must detach or download the Offer Form file to your local PC. All best and final offers are due by **2:00 p.m. EST on Wednesday September 15, 2010**. Only those offers submitted via the Secure FTP using the Offer Form referenced above will be considered for this review.

Texas state law mandates that all manufactures must register and be on file with the Texas Secretary of State's office in order to participate in the supplemental rebate program. Manufactures may verify registration at:

<http://www.sos.state.tx.us/corp/sosda/index.shtml>.

To register please visit the Texas Secretary of State website at:

[http://www.sos.state.tx.us/corp/foreign\\_outofstate.shtml](http://www.sos.state.tx.us/corp/foreign_outofstate.shtml)

HHSC has placed clinical edits on some drugs and drug classes, which may require prior authorization both for preferred and non-preferred drugs. To determine if any of the clinical edits currently in place impact any of the drugs being reviewed by the P&T Committee at this time, please visit the Texas Medicaid Clinical and Therapeutic Edits website at

[www.hhsc.state.tx.us/HCF/vdp/pt/Clinical\\_TherapeuticEdits.html](http://www.hhsc.state.tx.us/HCF/vdp/pt/Clinical_TherapeuticEdits.html)

HHSC encourages offers for supplemental rebates whereby the rebate amount is contingent upon a manufacturer's product being one of a limited number of products on the PDL within that product's therapeutic class.

Offers where the rebate for one or more products is contingent upon the inclusion of another product on the PDL from the same manufacturer will NOT be accepted by HHSC. Example: the supplemental rebate on “Product A” and/or “Product B” is contingent upon the inclusion of “Product C” on the PDL in addition to either “Product A” or “Product B”.

The following information is provided to assist you in completing and submitting your Offer Forms in addition to the instructions included on the Offer Form itself:

--Please direct questions regarding how to complete the Offer Form to Juanita Paige ([jpaige@magellanhealth.com](mailto:jpaige@magellanhealth.com)) or at 513-794-5288.

--Please direct questions regarding the Secure FTP site to Mike Phelps ([mdphelps@magellanhealth.com](mailto:mdphelps@magellanhealth.com)) or at 513-794-5287. Requests for user names and passwords may also be submitted via e-mail to Mike Phelps. User names and passwords will not be provided over the telephone.

--Please submit rebate offers only for the drug products on the list from the link referenced above. Rebates for other drug products may be solicited at a later date if/when they are scheduled for review by the P&T Committee.

--Do not change the column heading names, or add additional columns, blank rows, or contingencies to the Offer Form. Doing so may cause your Offer Form data to be rejected or not recognized by our systems.

--Prior to submitting, please re-name the Offer Form file as TXM Your Company Offer Form.xls. For example "TXM XYZ Corporation Offer Form.xls". Using any other file nomenclature may cause your Offer Form to be rejected or not recognized by our systems.

A confirmation of receipt will be sent to the e-mail address designated on the Contact Information tab of each Offer Form when the file is downloaded from the Secure FTP site to our internal servers (not when the file is uploaded to the FTP site). Allow at least 4 hours from the time of submission to the FTP site for the generation of the confirmation of receipt.

Please do not submit changes to manufacturer contact information with your Offer Form submissions. Such changes should be made using the Contact Information Form available at

<http://www.providersynergies.com/services/medicaid/default.asp?content=ManufacturerContactForm>

Clinical data pertinent to the drugs being reviewed may be submitted to Provider Synergies in electronic format only. Information should be sent to Chris Andrews, PharmD via e-mail ([cjandrews@magellanhealth.com](mailto:cjandrews@magellanhealth.com)) or CD-ROM (address to Chris

Andrews, PharmD, 10101 Alliance Rd. Ste 201 Cincinnati, Ohio 45242).

Rebate offers are due no later than **2:00 p.m. EST on Wednesday, September 15, 2010**. For those drugs selected as preferred at this P&T Committee meeting, rebates will begin to accrue on January 1, 2011. The term of the contract is one year.

Thank you for your consideration.

Juanita Paige  
Provider Synergies, LLC/Magellan Health Services, Inc.  
10101 Alliance Road Ste. 201  
Cincinnati, Ohio 45242

Phone (513) 794-5288  
Fax (888) 656-2735  
[jpaige@magellanhealth.com](mailto:jpaige@magellanhealth.com)  
[www.providersynergies.com](http://www.providersynergies.com)

**\*\*\*Confidentiality Notice\*\*\***

**This electronic message transmission contains information belonging to Magellan Health Services that is solely for the recipient named above and which may be confidential or privileged. MAGELLAN HEALTH SERVICES EXPRESSLY PRESERVES AND ASSERTS ALL PRIVILEGES AND IMMUNITIES APPLICABLE TO THIS TRANSMISSION. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of this communication is STRICTLY PROHIBITED. If you have received this electronic transmission in error, please notify us by telephone at (888) 411-6343 or ext. 34357. Thank you.**